Institut Curie, PSL Research University, SiRIC, Laboratory of Circulating Tumor Biomarkers, Paris, France; Institut Curie, PSL Research University, Department of Medical Oncology, Paris, France.
Institut Curie, PSL Research University, SiRIC, Laboratory of Circulating Tumor Biomarkers, Paris, France.
Mol Oncol. 2016 Mar;10(3):418-30. doi: 10.1016/j.molonc.2016.01.001. Epub 2016 Jan 12.
Over the past decade, technically reliable circulating tumor cell (CTC) detection methods allowed the collection of large datasets of CTC counts in cancer patients. These data can be used either as a dynamic prognostic biomarker or as tumor material for "liquid biopsy". Breast cancer appears to be the cancer type in which CTC have been the most extensively studied so far, with level-of-evidence-1 studies supporting the clinical validity of CTC count in both early and metastatic stage. This review summarizes and discusses the clinical results obtained in breast cancer patients, the issues faced by the molecular characterization of CTC and the biological findings about cancer biology and metastasis that were obtained from CTC.
在过去十年中，技术上可靠的循环肿瘤细胞（CTC）检测方法使得能够收集癌症患者CTC计数的大型数据集。这些数据既可以用作动态预后生物标志物，也可以用作“液体活检”的肿瘤材料。乳腺癌似乎是迄今为止对CTC研究最为广泛的癌症类型，证据等级为1的研究支持了CTC计数在早期和转移阶段的临床有效性。本综述总结并讨论了在乳腺癌患者中获得的临床结果、CTC分子特征面临的问题以及从CTC中获得的有关癌症生物学和转移的生物学发现。
